Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05014672




Registration number
NCT05014672
Ethics application status
Date submitted
10/08/2021
Date registered
20/08/2021
Date last updated
26/07/2024

Titles & IDs
Public title
A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness
Scientific title
TRANSFORM: A 24-week, Randomized, Placebo-controlled, Double-blind, Phase 2b Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness
Secondary ID [1] 0 0
2021-001810-13
Secondary ID [2] 0 0
GSN000350
Universal Trial Number (UTN)
Trial acronym
TRANSFORM
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Primary Biliary Cholangitis 0 0
Liver Stiffness 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Infection 0 0 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Setanaxib
Treatment: Drugs - Placebo

Experimental: Setanaxib 1200 mg/day - Participants will be administered setanaxib at a dose of 1200 mg/day for the 24-week double-blind treatment period.

Experimental: Setanaxib 1600 mg/day - Participants will be administered setanaxib at a dose of 1600 mg/day for the 24-week double-blind treatment period.

Placebo comparator: Placebo - Participants will be administered a placebo for the 24-week double-blind treatment period.


Treatment: Drugs: Setanaxib
Oral tablets, 400mg per tablet

Treatment: Drugs: Placebo
Oral tablets
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change from Baseline in ALP
Timepoint [1] 0 0
Baseline (Day 1) and Week 24
Secondary outcome [1] 0 0
Change from Baseline in Fatigue
Timepoint [1] 0 0
Baseline (Day 1) and Week 24
Secondary outcome [2] 0 0
Change from Baseline in Patient's Global Impression of Severity (PGIS) Fatigue
Timepoint [2] 0 0
Baseline (Day 1) and Week 24
Secondary outcome [3] 0 0
Change from Baseline in Patient's Global Impression of Change (PGIC) Fatigue
Timepoint [3] 0 0
Baseline (Day 1) and Week 24
Secondary outcome [4] 0 0
Change from Baseline in PBC-40 Fatigue Domain
Timepoint [4] 0 0
Baseline (Day 1) and Week 24
Secondary outcome [5] 0 0
Change from Screening in Liver Stiffness
Timepoint [5] 0 0
Screening (Day -28) and Week 24
Secondary outcome [6] 0 0
Change from Baseline in Worst Itch Numerical Scale Rating Scale (WI-NRS)
Timepoint [6] 0 0
Baseline (Day 1) and Week 24
Secondary outcome [7] 0 0
Change from Baseline in PBC-40 Itch Domain
Timepoint [7] 0 0
Baseline (Day 1) and Week 24
Secondary outcome [8] 0 0
Change from Baseline in PGIS Pruritus
Timepoint [8] 0 0
Baseline (Day 1) and Week 24
Secondary outcome [9] 0 0
Change from Baseline in PGIC Pruritus
Timepoint [9] 0 0
Baseline (Day 1) and Week 24
Secondary outcome [10] 0 0
Percentage of Participants Achieving a Biochemical Response to Setanaxib
Timepoint [10] 0 0
Baseline (Day 1) and Week 24
Secondary outcome [11] 0 0
Percentage of Participants with Treatment-Emergent Adverse Events (TEAEs)
Timepoint [11] 0 0
Up to Week 24
Secondary outcome [12] 0 0
Percentage of Participants Who Experience Adverse Events of Special Interest (AESIs)
Timepoint [12] 0 0
Up to Week 24

Eligibility
Key inclusion criteria
* Male or female participant aged =18 years, inclusive at the time of informed consent.
* Willing and able to give written informed consent and to comply with the requirements of the study.
* Definite or probable PBC diagnosis as demonstrated by the presence of =2 of the following 3 diagnostic factors:

* Documented history of elevated ALP levels =1.67×ULN of the local reference range.
* Documented history of positive antimitochondrial antibodies (AMA) titer or positive PBC-specific antibodies (anti-GP210 or anti-SP100 or antibodies against the major M2 components [PDC-E2, 2-oxo-glutaric acid dehydrogenase complex]).
* Historical liver biopsy consistent with PBC.
* Serum ALP =1.67×ULN at Screening.
* Liver stiffness measured by transient elastography (FibroScan®) of =8.8 kilopascals (kPa) and an interquartile range over median ratio (IQR/med) of =30% at Screening, are taken with the results expressed in kilopascals).
* Ursodeoxycholic acid (UDCA) prescriptional dose use for the past 6 months (at a stable dose for >3 months prior to Screening) OR intolerant to UDCA (last dose of UDCA >3 months prior to Screening). Intolerance to UDCA is defined as participants unable to tolerate the full-labelled dose of UDCA in PBC (13-15 mg/kg) due to frequently reported gastrointestinal symptoms such as diarrhea and abdominal pain.
* For participants receiving obeticholic acid (OCA), fenofibrate, or bezafibrate treatment for at least 6 months and stable dose for >3 months prior to Screening.
* For participants intolerant to OCA, OCA must have been discontinued >3 months prior to Screening.
* For participants previously treated with bezafibrate or fenofibrate, and these agents were discontinued prior to screening, they must have been discontinued >3 months prior to Screening.
* Female participants of childbearing potential must use a highly effective method of contraception to prevent pregnancy for =4 weeks before Randomization and must agree to continue strict contraception up to 90 days after the last dose of investigational medicinal product (IMP).

* For the purposes of this trial, women of childbearing potential are defined as "Fertile, following menarche and until becoming postmenopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy."
* Postmenopausal state is defined as no menses for 12 months without an alternative medical cause. In female participants who are not using hormonal contraception or hormonal replacement therapy but with suspected menopause and less than 12 months of amenorrhea, a high follicle stimulating hormone (FSH) level in the postmenopausal range will be required at Screening to confirm a postmenopausal state. Confirmation with more than one FSH measurement is required.
* Highly effective contraception is defined as methods that can achieve a failure rate of less than 1% per year when used consistently and correctly. These methods are:

* Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal)
* Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable)
* Intrauterine device
* Intrauterine hormone-releasing system
* Bilateral tubal occlusion
* Vasectomized partner
* Sexual abstinence (refraining from heterosexual intercourse during the entire period of risk associate with the study treatments). The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant. Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method are not acceptable methods of contraception. Female condom and male condom should not be used together.
* Female participants of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Baseline/Randomization before dosing.
* Male participants with female partners of childbearing potential must be willing to use a condom and require their partner to use a highly effective contraceptive method. This requirement begins at the time of informed consent and ends 90 days after receiving the last dose of IMP.
* Male participants must be willing not to donate sperm, and female study participants must be willing not to donate eggs, from Baseline until 90 days after the last dose of IMP.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* A positive pregnancy test or breastfeeding for female participants.
* Any historical or current hepatic decompensation event defined as variceal/portal hypertension bleed and/or hepatic encephalopathy, spontaneous bacterial peritonitis, ascites requiring treatment, or liver transplantation list inclusion.
* History of liver transplantation, current placement on a liver transplant list or current model for end stage liver disease (MELD) score of =12 unless the participant is on anticoagulant therapy, or a Child-Pugh Score of =6.
* Cirrhosis with complications, including history or presence of hepatocellular carcinoma.
* Total bilirubin >2×ULN. In case of total bilirubin elevation >ULN the Screening serum albumin must be within the reference range.
* Plasma alanine aminotransferase (ALT) >3×ULN and/or aspartate aminotransferase (AST) >3×ULN.
* International normalized ratio (INR) >1.2 unless participant is on anticoagulant therapy. One repeat blood sampling (with analysis by the central laboratory) can be performed at the discretion of the Investigator at Screening Visit 2 for participants who meet this exclusion criterion at Screening Visit 1. If this exclusion criterion is not met at Screening Visit 2, the participant may be eligible for the study.
* Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m^2, as calculated by the central laboratory using the chronic kidney disease-epidemiology collaboration (CKD- EPI) equation.
* Thyroid-stimulating hormone >ULN at Screening. One repeat blood sampling (with analysis by the central laboratory) can be performed at the discretion of the Investigator at Screening Visit 2 for participants who meet this exclusion criterion at Screening Visit 1. If this exclusion criterion is not met at Screening Visit 2, the participant may be eligible for the study.
* Competing etiology for liver disease (eg, hepatitis C [unless effectively cured of hepatitis C, with a sustained virologic response for at least 6 months prior to Screening], active hepatitis B [HBsAg positive], nonalcoholic steatohepatitis [NASH], alcoholic liver disease, autoimmune hepatitis, autoimmune hepatitis-PBC overlap syndrome, primary sclerosing cholangitis, Gilbert's Syndrome).
* Medical conditions that could cause nonhepatic increases in ALP (eg, Paget's disease).
* Known history of human immunodeficiency virus (HIV) infection.
* Surgery (eg, stomach bypass) or medical condition that might significantly affect absorption of medicines (as judged by the Investigator).
* Positive urine drug screen (if not due to prescriptional use of a concomitant medication, as confirmed by the Investigator) at Screening. Participants on stable methadone or buprenorphine maintenance treatment for at least 6 months prior to Screening Visit 1 may be included in the study. Medicinal cannabis and cannabidiol products are not exclusionary and may be allowed if the prescription and diagnosis are reviewed and approved by the Investigator.
* Participants receiving prohibited medications within 3 months of Screening Visit 1.
* Treatment with any investigational agent within 12 weeks of Screening Visit 1 or 5 half-lives of the IMP (if known) (whichever is longer) or current enrollment in an interventional clinical trial.
* Evidence of any of the following cardiac conduction abnormalities: A QTc Fridericia interval >450 milliseconds for males or >470 milliseconds for females, as calculated by the central reader. Participants with a second- or third-degree atrioventricular block are to be excluded.
* History of a malignancy within 5 years of Screening with the following exceptions:

* Adequately treated carcinoma in situ of the cervix.
* Adequately treated basal or squamous cell cancer or other localized nonmelanoma skin cancer.
* The occurrence of any acute infection requiring systemic antibiotic therapy within the 2 weeks prior to Screening Visit 1.
* A history of bone marrow disorder including aplastic anemia, or any current marked anemia defined as hemoglobin <10.0 g/dL.
* Prior treatment with setanaxib or participation in a previous setanaxib clinical trial.
* Unstable cardiovascular disease.
* Presence of any laboratory abnormality or condition that, in the opinion of the Investigator, could interfere with or compromise a participant's treatment, assessment, or compliance with the protocol and/or study procedures.
* Any other condition which, in the opinion of the Investigator, constitutes a risk or contraindication for the participation of the participant in the study, or that could interfere with the study objectives, conduct, or evaluation.
* Hypersensitivity or intolerance to setanaxib or to any of its excipients or placebo compounds.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
14/02/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
2/07/2024
Sample size
Target
Accrual to date
Final
76
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
John Hunter Hospital - New Lambton Heights
Recruitment hospital [3] 0 0
Mater Misericordiae - Hospital Brisbane - South Brisbane
Recruitment hospital [4] 0 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [5] 0 0
Eastern Health - Australia - Box Hill
Recruitment hospital [6] 0 0
Monash Medical Centre - Clayton
Recruitment hospital [7] 0 0
Fiona Stanley Hospital - Murdoch
Recruitment hospital [8] 0 0
Nepean Hospital - Kingswood
Recruitment hospital [9] 0 0
Liverpool Hospital - Liverpool
Recruitment hospital [10] 0 0
The Alfred Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2305 - New Lambton Heights
Recruitment postcode(s) [3] 0 0
4101 - South Brisbane
Recruitment postcode(s) [4] 0 0
5042 - Bedford Park
Recruitment postcode(s) [5] 0 0
3128 - Box Hill
Recruitment postcode(s) [6] 0 0
3168 - Clayton
Recruitment postcode(s) [7] 0 0
6150 - Murdoch
Recruitment postcode(s) [8] 0 0
2747 - Kingswood
Recruitment postcode(s) [9] 0 0
2170 - Liverpool
Recruitment postcode(s) [10] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Iowa
Country [6] 0 0
United States of America
State/province [6] 0 0
Kansas
Country [7] 0 0
United States of America
State/province [7] 0 0
Louisiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
Mississippi
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
North Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
South Dakota
Country [15] 0 0
United States of America
State/province [15] 0 0
Tennessee
Country [16] 0 0
United States of America
State/province [16] 0 0
Texas
Country [17] 0 0
United States of America
State/province [17] 0 0
Utah
Country [18] 0 0
United States of America
State/province [18] 0 0
Wisconsin
Country [19] 0 0
Austria
State/province [19] 0 0
Oberösterreich
Country [20] 0 0
Austria
State/province [20] 0 0
Styria
Country [21] 0 0
Austria
State/province [21] 0 0
Tyrol
Country [22] 0 0
Belgium
State/province [22] 0 0
Brussels
Country [23] 0 0
Belgium
State/province [23] 0 0
Flemish Brabant
Country [24] 0 0
Belgium
State/province [24] 0 0
Oost-Vlaanderen
Country [25] 0 0
Canada
State/province [25] 0 0
Alberta
Country [26] 0 0
Canada
State/province [26] 0 0
Nova Scotia
Country [27] 0 0
Canada
State/province [27] 0 0
Ontario
Country [28] 0 0
Canada
State/province [28] 0 0
Quebec
Country [29] 0 0
Canada
State/province [29] 0 0
Brampton
Country [30] 0 0
Czechia
State/province [30] 0 0
Prague
Country [31] 0 0
Czechia
State/province [31] 0 0
Hradec Králové
Country [32] 0 0
France
State/province [32] 0 0
Hauts-de-France
Country [33] 0 0
France
State/province [33] 0 0
Ile-de-France
Country [34] 0 0
France
State/province [34] 0 0
Isère
Country [35] 0 0
France
State/province [35] 0 0
Limousin
Country [36] 0 0
France
State/province [36] 0 0
Lorraine
Country [37] 0 0
France
State/province [37] 0 0
Occitanie
Country [38] 0 0
France
State/province [38] 0 0
Pays De La Loire
Country [39] 0 0
France
State/province [39] 0 0
Picardie
Country [40] 0 0
France
State/province [40] 0 0
Rhone-alpes
Country [41] 0 0
France
State/province [41] 0 0
Lille
Country [42] 0 0
France
State/province [42] 0 0
Marseille
Country [43] 0 0
France
State/province [43] 0 0
Nice
Country [44] 0 0
France
State/province [44] 0 0
Paris
Country [45] 0 0
Germany
State/province [45] 0 0
Bayern
Country [46] 0 0
Germany
State/province [46] 0 0
Hessen
Country [47] 0 0
Germany
State/province [47] 0 0
Niedersachsen
Country [48] 0 0
Germany
State/province [48] 0 0
Sachsen
Country [49] 0 0
Germany
State/province [49] 0 0
Homburg
Country [50] 0 0
Greece
State/province [50] 0 0
Heraklion
Country [51] 0 0
Greece
State/province [51] 0 0
Larissa
Country [52] 0 0
Hungary
State/province [52] 0 0
Budapest
Country [53] 0 0
Israel
State/province [53] 0 0
Haifa District
Country [54] 0 0
Israel
State/province [54] 0 0
Northern District
Country [55] 0 0
Israel
State/province [55] 0 0
Southern District
Country [56] 0 0
Israel
State/province [56] 0 0
Tel Aviv
Country [57] 0 0
Israel
State/province [57] 0 0
Haifa
Country [58] 0 0
Israel
State/province [58] 0 0
Jerusalem
Country [59] 0 0
Italy
State/province [59] 0 0
Milano
Country [60] 0 0
Italy
State/province [60] 0 0
Milan
Country [61] 0 0
Italy
State/province [61] 0 0
Monza And Brianza
Country [62] 0 0
Italy
State/province [62] 0 0
Ancona
Country [63] 0 0
Italy
State/province [63] 0 0
Messina
Country [64] 0 0
Italy
State/province [64] 0 0
Napoli
Country [65] 0 0
Italy
State/province [65] 0 0
Novara
Country [66] 0 0
New Zealand
State/province [66] 0 0
Auckland
Country [67] 0 0
New Zealand
State/province [67] 0 0
Wellington
Country [68] 0 0
New Zealand
State/province [68] 0 0
Dunedin
Country [69] 0 0
New Zealand
State/province [69] 0 0
Hamilton
Country [70] 0 0
Poland
State/province [70] 0 0
Bytom
Country [71] 0 0
Poland
State/province [71] 0 0
Myslowice
Country [72] 0 0
Poland
State/province [72] 0 0
Wroclaw
Country [73] 0 0
Spain
State/province [73] 0 0
Barcelona
Country [74] 0 0
Spain
State/province [74] 0 0
Santa Cruz De Tenerife
Country [75] 0 0
Spain
State/province [75] 0 0
Alicante
Country [76] 0 0
Spain
State/province [76] 0 0
Almería
Country [77] 0 0
Spain
State/province [77] 0 0
Córdoba
Country [78] 0 0
Spain
State/province [78] 0 0
Madrid
Country [79] 0 0
Spain
State/province [79] 0 0
Málaga
Country [80] 0 0
Spain
State/province [80] 0 0
Santiago
Country [81] 0 0
Spain
State/province [81] 0 0
Sevilla
Country [82] 0 0
Spain
State/province [82] 0 0
València
Country [83] 0 0
Spain
State/province [83] 0 0
Zaragoza
Country [84] 0 0
Sweden
State/province [84] 0 0
Uppsala
Country [85] 0 0
Switzerland
State/province [85] 0 0
Ticino
Country [86] 0 0
Switzerland
State/province [86] 0 0
Sankt Gallen
Country [87] 0 0
United Kingdom
State/province [87] 0 0
England
Country [88] 0 0
United Kingdom
State/province [88] 0 0
Scotland

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Calliditas Therapeutics Suisse SA
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary objective of this study is to evaluate the effect of setanaxib on alkaline phosphatase (ALP) at Week 24 in participants with PBC and with elevated liver stiffness and intolerance or inadequate response to ursodeoxycholic acid (UDCA).
Trial website
https://clinicaltrials.gov/study/NCT05014672
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05014672